<SEC-DOCUMENT>0001513162-20-000115.txt : 20200602
<SEC-HEADER>0001513162-20-000115.hdr.sgml : 20200602
<ACCEPTANCE-DATETIME>20200601200918
ACCESSION NUMBER:		0001513162-20-000115
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200601
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200602
DATE AS OF CHANGE:		20200601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		20935337

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=FONT-SIZE:11pt>UNITED STATES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=FONT-SIZE:11pt>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=FONT-SIZE:11pt>WASHINGTON, D.C.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=FONT-SIZE:11pt>FORM 8-K</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=FONT-SIZE:11pt>CURRENT REPORT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Pursuant to Section 13 or 15(d) of the</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Securities Exchange Act of 1934</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Date of Report (date of earliest event reported): <b>June 1, 2020</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u><font style=FONT-SIZE:11pt>BIOMERICA, INC.</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>(Exact Name of Registrant as Specified in its Charter)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <div align=center> <table width=633 bordercolor=transparent style=WIDTH:474.75pt cellpadding=0 cellspacing=0> <tr> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Delaware</font></p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=center><font style=FONT-SIZE:11pt>001-37863</font></p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center><font style=FONT-SIZE:11pt>95-2645573</font></p></td></tr> <tr> <td width=93 style="WIDTH:69.75pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=center><font style=FONT-SIZE:11pt>(State or Other Jurisdiction of Incorporation)</font></p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=83 style="WIDTH:62.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>(Commission File Number)</font></p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=138 style="WIDTH:103.5pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>(IRS Employer Identification Number)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>17571 Von Karman Ave.</font></p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt>Irvine, California 92614</font></h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>(Address of Principal Executive Offices</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Including Zip Code)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u><font style=FONT-SIZE:11pt>949-645-2111</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>(Registrant&#146;s Telephone Number,</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Including Area Code)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><b><font style=FONT-SIZE:11pt>Not applicable</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>(Former Name or Former Address if Changed</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>Since Last Report)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt 0in 0pt'><font style=FONT-SIZE:11pt><font style=FONT-FAMILY:Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><font style=FONT-FAMILY:Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><font style=FONT-FAMILY:Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt><font style=FONT-FAMILY:Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:3pt 0in 0pt; LINE-HEIGHT:120%'><font style=FONT-SIZE:11pt>Securities registered pursuant to Section 12(b) of the Act:</font></p> <div align=center> <table width=683 bordercolor=transparent style="WIDTH:512pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Title of each class</font></u></b></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Trading Symbol</font></u></b></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">Common Stock, par value $0.08</font></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">BMRA</font></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in -10pt 0pt 0in; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in -10pt 0pt 0in; LINE-HEIGHT:120%'><font style=FONT-SIZE:11pt>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font> </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt -10pt 0pt 0in; LINE-HEIGHT:120%'><font style=FONT-SIZE:11pt>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>1</font></p> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> <div style=PAGE-BREAK-BEFORE:always>&nbsp;</div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:11pt>Item 7.01 Regulation FD Disclosures.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt>On June 1, 2020, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing that it had signed agreements with Mayo Clinic to join its clinical trial for its InFoods product. It also announced that it had received a patent in Japan pertaining to its Infoods product. &nbsp;A copy of Biomerica&#146;s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt>The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b><font style=FONT-SIZE:11pt>Item 8.01 Other Events.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><a name=_Hlk39847039><font style=FONT-SIZE:11pt>On March 26, 2020, the Japanese Patent Office issued Biomerica&#146;s first Japanese patent pertaining to the Company&#146;s InFoods&#174; family of products that allow for a revolutionary new treatment option for patients suffering from IBS and several other disease states. &nbsp;&nbsp;Specifically, this patent &nbsp;(JP,6681907,B) contains numerous claims that broadly cover a product that enables physicians to identify patient-specific foods (e.g. pork, milk, shrimp, broccoli, chickpeas, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. It is estimated that about 19 million people in Japan suffer from IBS. </font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt>On May 28, 2020, the Company signed definitive agreements with Mayo Clinic to join the clinical trial for Biomerica&#146;s new InFoods&#174; diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.&nbsp; &nbsp;Mayo Clinic can now begin enrollment of patients in this trial.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b><font style="FONT-SIZE:11pt; COLOR:black">Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.25in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'><font style=FONT-SIZE:11pt>(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <div align=center> <table width=99% bordercolor=transparent style="WIDTH:99.42%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=9% nowrap style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center><font style=FONT-SIZE:11pt><font style=LINE-HEIGHT:115%>&nbsp;</font><b><u><font style=LINE-HEIGHT:115%>Number</font></u></b></font></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><font style="FONT-SIZE:11pt; LINE-HEIGHT:115%">&nbsp;&nbsp;</font></p></td> <td width=89% nowrap style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.7pt; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><b><u><font style="FONT-SIZE:11pt; LINE-HEIGHT:115%">Description</font></u></b></p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><font style=FONT-SIZE:11pt>99.1</font></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in -5.65pt 0pt 0in; LINE-HEIGHT:115%'><font style=FONT-SIZE:11pt>Press Release issued June 1, 2020.</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt'><font style=FONT-SIZE:11pt>2</font></p><b> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> <div style=PAGE-BREAK-BEFORE:always>&nbsp;</div></b> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in'><font style=FONT-SIZE:11pt>SIGNATURE</font></h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.3in 0pt 0in'><font style=FONT-SIZE:11pt>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <table width=723 bordercolor=transparent style="WIDTH:542.1pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Dated:&nbsp; June 2, 2020</font></p></td> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=261 colspan=2 nowrap style="HEIGHT:15.75pt; WIDTH:195.9pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=31 nowrap style="HEIGHT:15.75pt; WIDTH:23.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td> <td width=230 nowrap style="HEIGHT:15.75pt; WIDTH:172.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=31 nowrap style="HEIGHT:15.75pt; WIDTH:23.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By: </font></p></td> <td width=230 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:172.35pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">/s/ Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=31 nowrap style="HEIGHT:15.75pt; WIDTH:23.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=230 nowrap style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:172.35pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; BORDER-LEFT:0px; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15.75pt> <td width=191 nowrap style="HEIGHT:15.75pt; WIDTH:143.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=90 nowrap style="HEIGHT:15.75pt; WIDTH:67.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=31 nowrap style="HEIGHT:15.75pt; WIDTH:23.55pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <td width=230 nowrap style="HEIGHT:15.75pt; WIDTH:172.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:5.4pt; PADDING-RIGHT:5.4pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in' align=center><font style=FONT-SIZE:11pt>3</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p></div></body>
<!-- EDGAR Validation Code: B62050B2 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head> <title> Exhibit 99.1 </title> </head> <body vlink=#954f72 link=#0071bb lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 12pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:6pt 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:17.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><img src=graphic.jpg></font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:6pt 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:17.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Mayo Clinic joins Biomerica&#146;s InFoods&#174; Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial.&nbsp; </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:6pt 0in 0pt; LINE-HEIGHT:normal'><b></b>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica also announces its first Japanese patent has been granted for its InFoods&#174; IBS Diagnostic Guided Therapy technology&nbsp; </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal'><b></b>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">InFoods&#174; Diagnostic-Guided Therapy is designed to identify patient-specific foods,</font></b><b><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">that when removed from the diet, alleviate an individual's IBS symptoms</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:107%'><b></b>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:14.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Approximately 45 million Americans suffer from IBS<sup>1</sup> </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%'><b></b>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40" lang=ES>IRVINE, CA--(June 1, 2020) - Biomerica Inc. </font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">(NASDAQ: </font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">BMRA</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">) today announced they have signed definitive agreements with Mayo Clinic to join the clinical trial for Biomerica&#146;s</font> new InFoods&#174; <font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.&nbsp; &nbsp;Mayo Clinic is joining Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers for this study. Mayo Clinic can now begin enrollment of patients in this trial.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica has added several new, large medical centers and groups to assist with accelerating completion of the endpoint trial and to participate in the subsequent pivotal trial needed for final FDA clearance.&nbsp; Biomerica continues to add leading gastrointestinal ("GI") physicians operating in world-renowned centers to the InFoods&#174; IBS clinical study, who are potential users and advocates for this product once cleared by the FDA.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica also announced today that the Japanese Patent Office has issued Biomerica&#146; s first Japanese patent pertaining to the Company&#146;s InFoods&#174; family of products that allow for a revolutionary new treatment option for patients suffering from IBS and several other disease states. &nbsp;&nbsp;Specifically, this patent &nbsp;(JP,6681907,B) contains numerous claims that broadly cover a product that enables physicians to identify patient-specific foods (e.g. pork, milk, shrimp, broccoli, chickpeas, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. It is estimated that about 19 million people in Japan suffer from IBS.</font> </p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">It is estimated that over 45 million Americans suffer from IBS and the symptoms are often triggered by consumption of specific foods (which are unique in each sufferer).&nbsp; The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair physical and mental well-being of a patient and a person&#146;s ability to function both at home and in the workplace.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">1</font></p> <hr> <DIV style="PAGE-BREAK-BEFORE: always">&nbsp;</DIV> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">A clinical lab version of the product is being used in this clinical trial. &nbsp;However, the Company is also developing InFoods&#174; IBS DGT as a point-of-care product that allows physicians to perform the test in-office using a finger stick blood sample.&nbsp; A billable CPT code that can be used by both clinical labs and physicians' offices is already available for the InFoods&#174; IBS products. Market research conducted by a leading, independent pharmaceutical marketing research firm, determined that seventy percent (70%) of physicians surveyed would utilize the InFoods&#174; DGT without reimbursement and over 90% would utilize it with reimbursement.&nbsp; </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Importantly, the InFoods&#174; DGT can be used without or in conjunction with current pharmaceuticals to potentially improve patient outcomes. Since the InFoods&#174; product is a diagnostic-guided therapy and not a drug, it has no drug-type side effects.&nbsp;&nbsp; </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">The clinical trials are randomized, double-blinded, and placebo-controlled. Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, has completed its enrollment of patients for this endpoint study but will continue to participate in the final pivotal trial once that commences.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">This clinical endpoint trial is expected to be completed in approximately 6 months. However, due to the novel coronavirus&#146; impact on the U.S.&#146;s healthcare system, it may take longer. If all goes as expected, Biomerica plans to commence the final pivotal trial several months thereafter, which is needed for submission to the FDA for final clearance. &nbsp;The endpoint trial stratifies enrollment by the three main IBS subclasses (IBS-Constipation, IBS-Diarrhea and IBS-Mixed).&nbsp;&nbsp; There is currently no FDA cleared therapy for IBS-Mixed. &nbsp;The study design has already received a non-significant risk determination from FDA.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Zackary Irani, Chief Executive Officer of Biomerica, commented: &#147;We are excited to have Mayo Clinic join the InFoods&#174; IBS trial.&nbsp; &nbsp;IBS patients who desperately seek symptom relief will be the beneficiaries of this revolutionary disruptive technology. &nbsp;Also, we are pleased to have additional countries issue patents with broad claims that acknowledge the novel and innovative attributes of this technology platform that can be used to help patients that suffer from IBS and many other diseases.&#148; &nbsp;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">About Biomerica (NASDAQ: </font></b><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">BMRA</font></b><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">)</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; TEXT-ALIGN:justify; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories, for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:normal' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">2<br></font></p> <hr> <DIV style="PAGE-BREAK-BEFORE: always">&nbsp;</DIV> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 8pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company&#146;s tests, the rapidity of testing results, pricing of the Company&#146;s test kits, commencement of FDA clinical trials, completion of clinical trials, favorable outlook pertaining to clinical trial outcomes, the FDA&#146;s acceptance of clinical trials data, clearance from the FDA for the Company&#146;s products to be sold in the US, receipt of regulatory approvals for the Company&#146;s products to be sold outside of the US, demand for international orders, availability of the Company&#146;s test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation:&nbsp; results of studies testing the efficacy of the Company&#146;s test; regulatory approvals necessary prior to commercialization of the Company&#146;s test and or therapy; availability of the Company&#146;s test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our tests or therapy; competition from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company&#146;s ability to obtain patent protection on any aspects of its test technology. &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among other things; fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company competes and will be competing, the impact of the coronavirus on the Company&#146;s operations, revenues and the completion of the clinical trials, the and the Company's dependence on partners and strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt; LINE-HEIGHT:22.5pt'><b><font style="FONT-SIZE:11.5pt; FONT-FAMILY:Avenir; TEXT-TRANSFORM:uppercase">Contact Information</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.25in; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Company Spokesperson<br>949-645-2111<br></font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">www.biomerica.com</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.25in; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; VERTICAL-ALIGN:top; BACKGROUND:white; MARGIN:0in 0in 0pt; LINE-HEIGHT:107%'><font size=+0><font style='FONT-SIZE:9pt; FONT-FAMILY:"Calibri","sans-serif"; LINE-HEIGHT:107%'>1</font></font> <font style="FONT-SIZE:9pt; COLOR:#642a8f">The epidemiology of irritable bowel syndrome</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; VERTICAL-ALIGN:top; BACKGROUND:white; MARGIN:0in 0in 0pt; LINE-HEIGHT:107%'><font style="FONT-SIZE:9pt; COLOR:#642a8f">Clin Epidemiol</font><font style="FONT-SIZE:9pt; COLOR:#642a8f">. 2014; 6: 71&#150;80. .&nbsp;doi:&nbsp;&nbsp;</font><font style="FONT-SIZE:9pt; COLOR:#642a8f">10.2147/CLEP.S40245</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; VERTICAL-ALIGN:top; BACKGROUND:white; MARGIN:0in 0in 0pt; LINE-HEIGHT:107%'><font style="FONT-SIZE:9pt; COLOR:#642a8f">Caroline Canavan</font><font style="FONT-SIZE:9pt; COLOR:#642a8f">,&nbsp;</font><font style="FONT-SIZE:9pt; COLOR:#642a8f">Joe West</font><font style="FONT-SIZE:9pt; COLOR:#642a8f">,&nbsp;and&nbsp;</font><font style="FONT-SIZE:9pt; COLOR:#642a8f">Timothy Card</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.25in; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 8pt; LINE-HEIGHT:107%' align=center><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40; LINE-HEIGHT:107%">3</font></p></div></body>
<!-- EDGAR Validation Code: 6E4503B9 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graphic.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graphic.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  G .@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**_./\
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MP7]H8>&)]C9OF4ELMW;VE]+/H?:-Y_P3R^!=^/WOPF\!-[_V/"#^86L?4O\
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MOKU*MC/8)7YG.ZMWY95+VZ[;:G<^(?\ @WK\+!BWAWXK_$#1VZK]I\JZ"_\
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MU@\A)CBD.WS"V,G:LT\N<=E-?;=_^QS^W"GAH6%I^T5X/CC@A\J&.+24MSM
MP%#K:;EP!@$5X#HW_!'_ /:B\*?M3W/Q=TK4OAFGBF36;K6X7NM0EN(XYIVD
M))1K?!QYAQZ$ ]J]]U3X=_\ !0W5;"2W7QS\(K$RJ5\^"%?,CSW&ZU89_"OV
MW-,=0=#"X7 8C#N%*"3]HE+WNK5XRMMTW/Y+RK 5UB,7B\PP^)4ZLVU[-N/N
M]$[2C??KL?$/[%/B'2_@_P#\%-K?0/CAX0E\=>/3XJ&G2Z[=ZS)<_P!G7_F!
M$NBA!6<*VULN?E&& RH%<+\&_'Q^.G_!2?Q#\3;F,W5GH]_K7CYP>0D5C%/>
M0+]-T4*?B*^V/@;_ ,$.?'WP^N_&7Q#\5>,=&\4_%;4-.O\ ^PXUFF^R0ZE=
M121F]N+ATWNR>:SJ!']\ Y. *O\ _!,S_@BWXL_9W\;^/+KXHR^'+O2O%7A2
MZ\,Q1Z3>R32A+HJ)F^:-0I\M2 >?O5ZN(XGR>$<1B85E*?LXPT;LWKS<D7LM
M5M9:?,\C#<*YU.6&PTZ+C#VDJEVE=+3EYY+=Z/>[U^1\Z?\ !O-\.U^(G[=&
ML>)]0/VB;PQH-S>QO)\S&YN)$AW_ %V23<^]?MW7Y,?#K_@C_P#M*_L(?'"?
MQ5\%/&'A'6(7C>U'VUS;O>6S,&\JX@=#&>54Y63(*@@BO<]6U_\ X*#^)M*^
MP0Z%\&O#\TJ[#J,,I>2(_P!X*\LBY_X ?I7R/&-"AG.8+&X7%TO9N*2YI<K5
MNZ:OYGV/!5?$9+ESP.+PE7VBDV^6/,G?LT[;:'R/_P '$?Q0_P"%D?MF>&?!
MFFYNY?"NBQPR11_,PN[N0R>7@=S&+<X_VJH?#KX:K\:_^"R'PW^'L.VZT7X0
M1:;HCD<H%T:U$EQGV>\28>YDKZJ_8^_X(HZO\//C+-\6_B_XIL_B!\0(+AM6
MLK&)Y#9G4/OI//.ZAY"KX( 154@'Y@ *T?\ @E1_P2_^(/[*?[2'C7XC_$V\
M\.7^K:]9206CZ;=R7#&6XN!-<2-OC3!.Q0.N=S5[CXCRS!Y9+"82LI.C2<4]
MN:<]W%/7W=7?S/"_U:S3&9K'&8NBXJO54I+?EIT]E)K3WM%;^Z?(?P2G'[&_
M_!>Z[TV5UM-,N_%E[8$.=J"VU%':#)Z #SX3_P !KHOVK/B1KW_!:O\ X*$:
M1\,O!%W*GPV\)32+]NC&81"C 76I,.A+<1P@]<IT\QJ]G_X*J?\ !';XB_M=
M_M72>// 5UX6M[+4=*M8;T:C?26\WVJ+='D!8G!7REBYSG(/%?27_!+#_@GE
M;?L"? ^6TU)K&_\ '7B*07&N7]MEHP%R(K:)B 3&@).2!N9V/3 &.-XDRREA
M:6<TYJ>+5*--1_EEK>;]-;?\'3? \,9I5Q=;):D'#!NK*HY?S1TY8+ULK_?T
MU_/36/ _A_Q-_P %R_"/@O0[:"R\&?"FYLK*VC)REM;:3:?:YBY[DS1S%B>2
MS$GDUXE^RW\.?&'_  4'_P""BNI7_A;Q$?"OB'5=4O\ Q7'K+1-(=,*RM*C
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MVUI$TTK[2=B*"6.!R> >E>$R?\%/_@@H^7QF\GLNCWW]81116<YN.Q^O^%_
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9C<:U+&5I5&OYI.7YMD]%%%!P!1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
